Vivet Therapeutics recieves €37.5 million in a Series A financing for advancement in metabolic diseases treatment

Vivet Therapeutics announced that it has recieved €37.5 million in a Series A financing round for advancement in developing gene therapies for treatment of rare inherited metabolic diseaase including Wilson Disease, progressive familial intrahepatic cholestasis type 2 (PFIC2), progressive familial intrahepatic cholestasis type 3 (PFIC3) and citrullinemia type I.

The round of raising funds consists of leading international life sciences investors led by Novartis Venture Fund and Columbus Venture Partners, and including Roche Venture Fund, HealthCap, Kurma Partners and Ysios Capital.

Vivet’s lead program, VTX801, is a novel investigational gene therapy targeting Wilson Disease. This rare genetic disorder is caused by a defective gene in liver cells encoding the ATP7B protein, which reduces the liver’s ability to regulate copper levels in the liver and other tissues causing severe hepatic and neurologic symptoms, leading to liver transplantation and potentially death. VTX801 uses a novel modified AAV vector to transport a truncated functional version of the ATP7B gene into the liver cells carrying the defective gene to treat the underlying cause of the disease; to restore copper metabolism, reduce liver damage and improve liver function.

Vivet’s Co-founder & CEO, Jean-Philippe Combal said that Vivet is delighted to have attracted such a substantial investment from these high profile life sciences investors. This fundraising reflects their shared excitement about the potential of their lead candidate VTX801 and their technology for generating further novel gene therapies targeting rare inherited metabolic diseases. Early results from preclinical studies with VTX801 are very promising, and they are now well funded to advance this candidate into the clinic, while developing our portfolio and technologies.